ATE319429T1 - Verwendung von einfachen aminosäuren zur herstellung von porösen partikeln - Google Patents

Verwendung von einfachen aminosäuren zur herstellung von porösen partikeln

Info

Publication number
ATE319429T1
ATE319429T1 AT00957716T AT00957716T ATE319429T1 AT E319429 T1 ATE319429 T1 AT E319429T1 AT 00957716 T AT00957716 T AT 00957716T AT 00957716 T AT00957716 T AT 00957716T AT E319429 T1 ATE319429 T1 AT E319429T1
Authority
AT
Austria
Prior art keywords
amino acids
porous particles
particles
produce porous
simple amino
Prior art date
Application number
AT00957716T
Other languages
German (de)
English (en)
Inventor
Richard P Batycky
Michael M Lipp
Ralph W Niven
Original Assignee
Advanced Inhalation Res Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Advanced Inhalation Res Inc filed Critical Advanced Inhalation Res Inc
Application granted granted Critical
Publication of ATE319429T1 publication Critical patent/ATE319429T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0082—Lung surfactant, artificial mucus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Biophysics (AREA)
  • Otolaryngology (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT00957716T 1999-08-25 2000-08-23 Verwendung von einfachen aminosäuren zur herstellung von porösen partikeln ATE319429T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/382,959 US6586008B1 (en) 1999-08-25 1999-08-25 Use of simple amino acids to form porous particles during spray drying

Publications (1)

Publication Number Publication Date
ATE319429T1 true ATE319429T1 (de) 2006-03-15

Family

ID=23511119

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00957716T ATE319429T1 (de) 1999-08-25 2000-08-23 Verwendung von einfachen aminosäuren zur herstellung von porösen partikeln

Country Status (11)

Country Link
US (8) US6586008B1 (enExample)
EP (2) EP1637128A3 (enExample)
JP (1) JP2003507412A (enExample)
AT (1) ATE319429T1 (enExample)
AU (1) AU764738B2 (enExample)
CA (1) CA2382651C (enExample)
DE (1) DE60026544T2 (enExample)
DK (1) DK1210068T3 (enExample)
ES (1) ES2258981T3 (enExample)
PT (1) PT1210068E (enExample)
WO (1) WO2001013893A2 (enExample)

Families Citing this family (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020052310A1 (en) * 1997-09-15 2002-05-02 Massachusetts Institute Of Technology The Penn State Research Foundation Particles for inhalation having sustained release properties
US6458338B1 (en) * 1998-09-22 2002-10-01 Aeropharm Technology Incorporated Amino acid stabilized medicinal aerosol formulations
US6858199B1 (en) 2000-06-09 2005-02-22 Advanced Inhalation Research, Inc. High efficient delivery of a large therapeutic mass aerosol
US6749835B1 (en) * 1999-08-25 2004-06-15 Advanced Inhalation Research, Inc. Formulation for spray-drying large porous particles
US6613308B2 (en) * 2000-09-19 2003-09-02 Advanced Inhalation Research, Inc. Pulmonary delivery in treating disorders of the central nervous system
US20020150626A1 (en) * 2000-10-16 2002-10-17 Kohane Daniel S. Lipid-protein-sugar particles for delivery of nucleic acids
PL365736A1 (en) * 2001-02-06 2005-01-10 Innovata Biomed Limited Bimodal dry powder formulation for inhalation
US6848197B2 (en) 2001-04-18 2005-02-01 Advanced Inhalation Research, Inc. Control of process humidity to produce large, porous particles
US20050123509A1 (en) * 2001-10-19 2005-06-09 Lehrman S. R. Modulating charge density to produce improvements in the characteristics of spray-dried proteins
US20050013867A1 (en) * 2001-10-19 2005-01-20 Lehrman S. Russ Use of proton sequestering agents in drug formulations
AU2002346424A1 (en) * 2001-11-19 2003-06-10 Becton, Dickinson And Company Pharmaceutical compositions in particulate form
JP2005511629A (ja) * 2001-11-20 2005-04-28 アドバンスト インハレーション リサーチ，インコーポレイテッド 持続作用生成物送達用組成物
WO2003053411A1 (en) * 2001-12-19 2003-07-03 Nektar Therapeutics Pulmonary delivery of aminoglycosides
KR20040093155A (ko) * 2002-03-18 2004-11-04 야마노우치세이야쿠 가부시키가이샤 흡입용 분말 의약조성물 및 이의 제조방법
US7754242B2 (en) * 2002-03-20 2010-07-13 Alkermes, Inc. Inhalable sustained therapeutic formulations
US20110123574A1 (en) * 2002-03-20 2011-05-26 Alkermes, Inc. Inhalable sustained therapeutic formulations
ES2718455T3 (es) 2002-03-20 2019-07-02 Civitas Therapeutics Inc Formulaciones terapéuticas sostenidas inhalables
US7132100B2 (en) * 2002-06-14 2006-11-07 Medimmune, Inc. Stabilized liquid anti-RSV antibody formulations
US7425618B2 (en) * 2002-06-14 2008-09-16 Medimmune, Inc. Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
US20040204439A1 (en) * 2003-04-14 2004-10-14 Staniforth John Nicholas Composition, device, and method for treating sexual dysfunction via inhalation
WO2004093848A2 (en) * 2003-04-14 2004-11-04 Vectura Ltd Dry power inhaler devices and dry power formulations for enhancing dosing efficiency
KR20120080243A (ko) * 2003-05-28 2012-07-16 노바르티스 아게 아미노산 및/또는 인지질로 부분 또는 완전 코팅된 수불용성 활성제 미립자의 제조를 위한 알코올성 수용액의 분무 건조법
WO2005025535A2 (en) * 2003-09-15 2005-03-24 Vectura Limited Methods for preparing pharmaceutical compositions
CA2554973A1 (en) * 2004-02-10 2005-08-25 Advanced Inhalation Research, Inc. Particles for inhalation rapid release properties
US7611709B2 (en) 2004-05-10 2009-11-03 Boehringer Ingelheim Pharma Gmbh And Co. Kg 1,4 O-linked saccharose derivatives for stabilization of antibodies or antibody derivatives
US7723306B2 (en) 2004-05-10 2010-05-25 Boehringer Ingelheim Pharma Gmbh & Co. Kg Spray-dried powder comprising at least one 1,4 O-linked saccharose-derivative and methods for their preparation
SG153833A1 (en) 2004-06-18 2009-07-29 Novartis Vaccines & Diagnostic Methods of treatment of endobronchial infections
WO2006014930A2 (en) * 2004-07-26 2006-02-09 Cotherix, Inc. Treatment of pulmonary hypertension by inhaled iloprost with a microparticle formulation
BRPI0517374A (pt) * 2004-10-29 2008-10-07 Harvard College formulação para tratamento ou prevenção de infecção respiratória, método para tratamento
US20060105051A1 (en) * 2004-11-18 2006-05-18 Blair Jackson Manufacture of particles for pulmonary drug delivery by carbon dioxide assisted nebulization
GB0425758D0 (en) 2004-11-23 2004-12-22 Vectura Ltd Preparation of pharmaceutical compositions
US20060134009A1 (en) * 2004-12-16 2006-06-22 Daniel Deaver Low dose corticosteroid powders for inhalation
RS55114B1 (sr) 2005-05-18 2016-12-30 Raptor Pharmaceuticals Inc Aerosolizovani fluorohinoloni i njihove upotrebe
US8524735B2 (en) 2005-05-18 2013-09-03 Mpex Pharmaceuticals, Inc. Aerosolized fluoroquinolones and uses thereof
GB0524194D0 (en) * 2005-11-28 2006-01-04 Univ Aston Respirable powders
ES2473665T3 (es) * 2005-11-28 2014-07-07 Verrow Pharmaceuticals, Inc. Composiciones útiles para reducir la nefrotoxicidad y los métodos de uso de las mismas
US20070219127A1 (en) * 2006-03-20 2007-09-20 Walt John G Cyclosporin a compositions
DE102006030164A1 (de) * 2006-06-29 2008-01-03 Boehringer Ingelheim Pharma Gmbh & Co. Kg Inhalative Pulver
WO2008130220A1 (en) * 2007-04-20 2008-10-30 N.V. Nutricia Process for dispersing amino acids
NO2344129T3 (enExample) 2008-10-07 2018-07-21
PT2346509T (pt) 2008-10-07 2020-08-05 Horizon Orphan Llc Inalação de levofloxacina para redução da inflamação pulmonar
GB0908129D0 (en) * 2009-05-12 2009-06-24 Innovata Ltd Composition
EP2435025B1 (en) * 2009-05-29 2016-07-06 Pearl Therapeutics, Inc. Respiratory delivery of active agents
US8815258B2 (en) 2009-05-29 2014-08-26 Pearl Therapeutics, Inc. Compositions, methods and systems for respiratory delivery of two or more active agents
BR112012004692B8 (pt) 2009-09-04 2021-05-25 Mpex Pharmaceuticals Inc solução que compreende levofloxacina para uso em um método para tratar a fibrose cística em um ser humano
WO2012106382A1 (en) 2011-01-31 2012-08-09 Genoa Pharmaceuticals, Inc. Aerosol pirfenidone and pyridone analog compounds and uses thereof
US9572774B2 (en) 2011-05-19 2017-02-21 Savara Inc. Dry powder vancomycin compositions and associated methods
AU2012254999B2 (en) * 2011-05-19 2016-02-11 Savara, Inc. Dry powder vancomycin compositions and associated methods
CN102225058A (zh) * 2011-06-22 2011-10-26 中国药科大学 磷酸奥司他韦吸入粉雾剂及其制备方法
WO2014074797A1 (en) 2012-11-09 2014-05-15 Civitas Therapeutics, Inc. Ultra low density pulmonary powders
AU2014212109B2 (en) 2013-02-01 2018-05-31 Glialogix, Inc. Compositions and methods for the treatment of neurodegenerative and other diseases
JP6454323B2 (ja) 2013-03-15 2019-01-16 パール セラピューティクス，インコーポレイテッド 粒子状結晶性材料のコンディショニングのための方法及びシステム
AU2014296032A1 (en) 2013-07-31 2016-03-17 Windward Pharma, Inc. Aerosol tyrosine kinase inhibitor compounds and uses thereof
NZ722927A (en) 2014-01-10 2022-07-29 Avalyn Pharma Inc Aerosol pirfenidone and pyridone analog compounds and uses thereof
DK3104853T3 (da) 2014-02-10 2019-12-09 Respivant Sciences Gmbh Behandling med mastcellestabilisatorer til systemiske forstyrrelser
WO2015120392A1 (en) 2014-02-10 2015-08-13 Patara Pharma, LLC Mast cell stabilizers for lung disease treatment
EP3174893B1 (en) * 2014-07-30 2020-05-06 Genome Protection, Inc. Flagellin compositions and uses
GB201415381D0 (en) * 2014-08-29 2014-10-15 Algipharma As Inhalable powder formulations of alginate oligomers
DK3212212T3 (da) 2014-10-31 2020-12-21 Univ Monash Pulverformulering
MA40910A (fr) 2014-11-07 2017-09-12 Civitas Therapeutics Inc Poudres de rapamycine pour administration pulmonaire
EP3331522A1 (en) 2015-08-07 2018-06-13 Patara Pharma LLC Methods for the treatment of mast cell related disorders with mast cell stabilizers
US10265296B2 (en) 2015-08-07 2019-04-23 Respivant Sciences Gmbh Methods for the treatment of systemic disorders treatable with mast cell stabilizers, including mast cell related disorders
US9585835B1 (en) * 2015-09-16 2017-03-07 Sansa Corporation (Barbados) Inc. Inhalable nicotine formulations and methods of making and using the same
JP6953414B2 (ja) * 2016-01-20 2021-10-27 フラリー パウダーズ エルエルシーＦｌｕｒｒｙ Ｐｏｗｄｅｒｓ，Ｌｌｃ 親油性成分を含む吸入に好適な分散性の噴霧乾燥粉末を製造する方法
US11833118B2 (en) 2016-01-20 2023-12-05 Flurry Powders, Llc Encapsulation of lipophilic ingredients in dispersible spray dried powders suitable for inhalation
MA45451A (fr) * 2016-06-24 2019-05-01 Civitas Therapeutics Inc Formulations tensioactives destinées à l'inhalation
WO2018002779A1 (en) * 2016-06-30 2018-01-04 Philip Morris Products S.A. Nicotine particles
US20190133940A1 (en) * 2016-06-30 2019-05-09 Philip Morris Products S.A. Nicotine particles and compositions
AU2017321495A1 (en) 2016-08-31 2019-03-21 Respivant Sciences Gmbh Cromolyn compositions for treatment of chronic cough due to idiopathic pulmonary fibrosis
JP2019531308A (ja) 2016-10-07 2019-10-31 レシュピファント サイエンシス ゲゼルシャフト ミット ベシュレンクター ハフトゥングＲｅｓｐｉｖａｎｔ Ｓｃｉｅｎｃｅｓ Ｇｍｂｈ 肺線維症の治療のためのクロモリン組成物
US20180110760A1 (en) 2016-10-21 2018-04-26 Glialogix, Inc. Compositions and methods for the treatmentof neurodegenerative and other diseases
CA3048677A1 (en) * 2017-03-07 2018-09-13 Philip Morris Products S.A. Inhalable nicotine formulations, and methods of making and using thereof
GB2577420B (en) 2017-05-22 2022-07-06 Insmed Inc Glycopeptide derivative compounds and uses thereof
EP3727418A4 (en) * 2017-12-21 2021-10-27 Civitas Therapeutics, Inc. SURFACTANT FORMULATIONS FOR INHALATION
EP3727353A4 (en) * 2017-12-21 2021-10-13 Civitas Therapeutics, Inc. SURFACTANT FORMULATIONS FOR INHALATION
CN112703000B (zh) 2018-07-23 2024-05-31 特雷维治疗股份有限公司 慢性咳嗽、呼吸急促和呼吸困难的治疗
AU2021206252A1 (en) 2020-01-10 2022-07-28 Trevi Therapeutics, Inc. Methods of administering nalbuphine

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4069819A (en) 1973-04-13 1978-01-24 Societa Farmaceutici S.P.A. Inhalation device
IT1228459B (it) 1989-02-23 1991-06-19 Phidea S R L Inalatore con svuotamento regolare e completo della capsula.
SE9302777D0 (sv) 1993-08-27 1993-08-27 Astra Ab Process for conditioning substances
US5874063A (en) 1991-04-11 1999-02-23 Astra Aktiebolag Pharmaceutical formulation
US6582728B1 (en) 1992-07-08 2003-06-24 Inhale Therapeutic Systems, Inc. Spray drying of macromolecules to produce inhaleable dry powders
DK0679088T3 (da) 1992-09-29 2002-10-28 Inhale Therapeutic Syst Pulmonal levering af aktive fragmenter af parathyreoideaea hormon
US6051256A (en) 1994-03-07 2000-04-18 Inhale Therapeutic Systems Dispersible macromolecule compositions and methods for their preparation and use
CA2183577C (en) 1994-03-07 2007-10-30 John S. Patton Methods and compositions for pulmonary delivery of insulin
ATE299892T1 (de) 1994-05-18 2005-08-15 Nektar Therapeutics Methoden und zusammensetzungen für die trockenpuderarznei aus interferonen
GB9501841D0 (en) 1995-01-31 1995-03-22 Co Ordinated Drug Dev Improvements in and relating to carrier particles for use in dry powder inhalers
US6165463A (en) 1997-10-16 2000-12-26 Inhale Therapeutic Systems, Inc. Dispersible antibody compositions and methods for their preparation and use
US6019968A (en) 1995-04-14 2000-02-01 Inhale Therapeutic Systems, Inc. Dispersible antibody compositions and methods for their preparation and use
ES2237767T3 (es) 1995-04-14 2005-08-01 Nektar Therapeutics Composiciones farmaceuticas en polvo que tienen una dispersabilidad mejorada.
US6258341B1 (en) 1995-04-14 2001-07-10 Inhale Therapeutic Systems, Inc. Stable glassy state powder formulations
GB9515182D0 (en) 1995-07-24 1995-09-20 Co Ordinated Drug Dev Improvements in and relating to powders for use in dry powder inhalers
US5855913A (en) 1997-01-16 1999-01-05 Massachusetts Instite Of Technology Particles incorporating surfactants for pulmonary drug delivery
US5874064A (en) 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
US5985309A (en) 1996-05-24 1999-11-16 Massachusetts Institute Of Technology Preparation of particles for inhalation
JP4233608B2 (ja) * 1996-10-15 2009-03-04 塩野義製薬株式会社 自己抗体測定方法
ATE287257T1 (de) 1997-01-16 2005-02-15 Massachusetts Inst Technology Zubereitung von partikelhaltigen arzneimitteln zur inhalation
AU750567B2 (en) 1997-09-29 2002-07-25 Novartis Ag Stabilized preparations for use in nebulizers
GB9827145D0 (en) 1998-12-09 1999-02-03 Co Ordinated Drug Dev Improvements in or relating to powders

Also Published As

Publication number Publication date
US20070104658A1 (en) 2007-05-10
US20160287517A1 (en) 2016-10-06
US8268358B2 (en) 2012-09-18
PT1210068E (pt) 2006-07-31
US20080160098A1 (en) 2008-07-03
CA2382651A1 (en) 2001-03-01
EP1210068A2 (en) 2002-06-05
JP2003507412A (ja) 2003-02-25
WO2001013893A2 (en) 2001-03-01
DE60026544T2 (de) 2007-01-11
US20080160092A1 (en) 2008-07-03
US20170354602A1 (en) 2017-12-14
EP1637128A3 (en) 2008-03-05
US6586008B1 (en) 2003-07-01
US9333174B2 (en) 2016-05-10
US20130071440A1 (en) 2013-03-21
EP1210068B1 (en) 2006-03-08
DE60026544D1 (de) 2006-05-04
CA2382651C (en) 2009-11-24
ES2258981T3 (es) 2006-09-16
WO2001013893A3 (en) 2001-05-03
US20120020887A1 (en) 2012-01-26
EP1637128A2 (en) 2006-03-22
AU764738B2 (en) 2003-08-28
DK1210068T3 (da) 2006-07-17
AU6929600A (en) 2001-03-19

Similar Documents

Publication Publication Date Title
ATE319429T1 (de) Verwendung von einfachen aminosäuren zur herstellung von porösen partikeln
DE69921941D1 (de) Verfahren zur Herstellung von pharmazeutischen Wirkstoffpartikeln
EP2298355A3 (en) Albumin fusion proteins
AU4094196A (en) Improvements in or relating to contrast agents
ATE97325T1 (de) Konzentriertes und stabilisiertes ultraschallagens vom mikrobubbletyp zur bilderzeugung und herstellungsverfahren.
FI911986A0 (fi) Farmaceutiska foereningar.
DE69802483D1 (de) Verfahren zur Herstellung von hydrophober Fällungkieselsäure
ITRM920590A0 (it) Sistema per la realizzazione distrutture in fibra di carbonio, e procedimento per detto, particolarmente idoneo per applicazioni aeronautiche.
TR200100074T2 (tr) Nevrotrofik büyüme faktörü
ATE285755T1 (de) Grosse poröse partikel erhältlich durch sprühtrocknung und geeignet zur pulmonalen anwendung
DE59711908D1 (de) Verfahren zur Herstellung von Salzen von Säuregruppen tragenden pharmazeutischen Wirkstoffen
DE69923906D1 (de) Verfahren zur Herstellung von Pyrazolo-(4,3-d)pyrimidin-7-ones und Zwischenprodukte davon
DE69315388D1 (de) Aus bakteriellen Proteinen bestehender Extrakt, Verfahren zur dessen Herstellung und diesen Extrakt enthaltende pharmazeutische Zusammensetzung
HU9203774D0 (en) Method for producing lipaze derivatives stimulated by human bile salt and pharmaceutical preparatives containing said compounds
ATE492260T1 (de) Kosmetische zusammensetzung, mit oberflächenhydrophobierter kieselsäure beschichtete metalloxidteilchen, sol von mit oberflächenhydrophobierter kieselsäure beschichtete kieselsäurebeschichteten metalloxiden und verfahren zur herstellung derselben.
DE60036758D1 (de) Verfahren zur Herstellung von optisch aktiver 3,3,3-Trifluor-2-hydroxy-2-methylpropionsäure und deren Salze
DE69813053D1 (de) Verfahren zur Herstellung von optisch aktiven Azetidin-2-Carbonsäurederivaten
DE69711207D1 (de) Natrium-salz von [poly-(2,5-dihydroxyphenylen)]-4-thioschwefelsäure mit linearer struktur zur regulierung des zellmetabolismus und herstellung davon
DE60003961D1 (de) Wässriges Verfahren zur Herstellung von linearen Chinacridonen mit reduzierter Teilchengrösse
DE69801302D1 (de) Verfahren zur Herstellung fester Lösungen von Chinacridonen
DE69814204D1 (de) Verfahren zur Herstellung von 2,2'-bis(Hydroxymethyl)alkanal und 2,2'-bis(Hydroxymethyl)alkansäure
DE69431097D1 (de) Verfahren zur Herstellung von humanem Serumalbumin
NO20005391D0 (no) Nye oktahydro-6,10-diokso-6H-pyridazino[1,2-a][1,2]diazepin-1- karboksylsyrederivater, fremgangsmÕte for fremstilling av disse samt deres anvendelse for fremstilling av terapeutisk aktive preparater
DE59504636D1 (de) Verfaharen zur herstellung von carboxy-arensulfonsäuren und deren carbonsäurederivaten
DE59911562D1 (de) Latent vernetzende wässerige dispersionen enthaltend ein polyurethan

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1210068

Country of ref document: EP

EEIH Change in the person of patent owner